



David Bomze

Kontakt

David Bomze

Publikationen (20)

Knopf P, Stowbur D, Hoffmann S, Hermann N, Maurer A, Bucher V, Poxleitner M, Tako B, Sonanini D, Krishnamachary B, Sinharay S, Fehrenbacher B, Gonzalez-Menendez I, Reckmann F, Bomze D, Flatz L, Kramer D, Schaller M, Forchhammer S, Bhujwala Z, Quintanilla-Martinez L, Schulze-Osthoff K, Pagel M, Fransen M, Röcken M, Martins A, Pichler B, Ghoreschi K, Kneilling M. Acidosis-mediated increase in IFN- γ -induced PD-L1 expression on cancer cells as an immune escape mechanism in solid tumors. *Mol Cancer* 2023; 22:207.

Purde M, Cupovic J, Palmowski Y, Makky A, Schmidt S, Rochwarger A, Hartmann F, Stemeseder F, Lercher A, Abdou M, Bomze D, Besse L, Berner F, Tüting T, Hölzel M, Bergthaler A, Kochanek S, Ludewig B, Lauterbach H, Orlinger K, Bald T, Schietinger A, Schürch C, Ring S, Flatz L. A replicating LCMV-based vaccine for the treatment of solid tumors. *Mol Ther* 2023

Lichtensteiger C, Koblischke M, Berner F, Jochum A, Sinnberg T, Balciunaite B, Purde M, Walter V, Abdou M, Hofmeister K, Kohler P, Vernazza P, Albrich W, Kahlert C, Zoufaly A, Traugott M, Kern L, Pietsch U, Kleger G, Filipovic M, Kneilling M, Cozzio A, Pop O, Bomze D, Bergthaler A, Hasan A, Aberle J, Flatz L. Autoreactive T cells targeting type II pneumocyte antigens in COVID-19 convalescent patients. *J Autoimmun* 2023; 140:103118.

Sinnberg T, Lichtensteiger C, Ali O, Pop O, Risch L, Brugger S, Velic A, Bomze D, Kohler P, Vernazza P, Albrich W, Kahlert C, Abdou M, Wyss N, Hofmeister K, Niessner H, Zinner C, Gilardi M, Tzankov A, Röcken M, Dulovic A, Shambat S, Ruetalo N, Buehler P, Scheier T, Jochum W, Kern L, Henz S, Schneider T, Kuster G, Lampart M, Siegemund M, Bingisser R, Schindler M, Schneiderhan-Marra N, Kalbacher H, McCoy K, Spengler W, Brutsche M, Macek B, Twerenbold R, Penninger J, Matter M, Flatz L, Jochum A. Pulmonary Surfactant Proteins Are Inhibited by Immunoglobulin A Autoantibodies in Severe COVID-19. *Am J Respir Crit Care Med* 2023; 207:38-49.

Berner F, Bomze D, Lichtensteiger C, Walter V, Niederer R, Hasan Ali O, Wyss N, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Abdou M, Diem S, Knöpfli S, Sinnberg T, Hofmeister K, Cheng H, Toma M, Klümper N, Purde M, Pop O, Jochum A, Pascolo S, Jörger M, Früh M, Jochum W, Rammensee H, Läubli H, Hölzel M, Neeffes J, Walz J, Flatz L. Autoreactive napsin A-specific T cells are enriched in lung tumors and inflammatory lung lesions during immune checkpoint blockade. *Sci Immunol* 2022; 7:eabn9644.

Berner F, Niederer R, Luimstra J, Pop O, Jochum A, Purde M, Hasan Ali O, Bomze D, Bauer J, Freudenmann L, Marcu A, Wolfschmitt E, Haen S, Gross T, Dubbelaar M, Abdou M, Baumgaertner P, Appenzeller C, Cicin-Sain C, Lenz T, Speiser D, Ludewig B, Driessen C, Jörger M, Früh M, Jochum W, Cozzio A, Rammensee H, Walz J, Neeffes J, Flatz L. Keratinocyte differentiation antigen-specific T cells in immune checkpoint inhibitor-treated NSCLC patients are associated with improved survival. *Oncoimmunology* 2021; 10:2006893.

Hasan Ali O, Bomze D, Risch L, Brugger S, Paprotny M, Weber M, Thiel S, Kern L, Albrich W, Kohler P, Kahlert C, Vernazza P, Bühler P, Schüpbach R, Gómez-Mejía A, Popa A, Bergthaler A, Penninger J, Flatz L. Erratum to: Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. *Clin Infect Dis* 2021; 73:1746.

Hasan Ali O, Penninger J, Bergthaler A, Popa A, Gómez-Mejía A, Schüpbach R, Bühler P, Vernazza P, Kahlert C, Kohler P, Albrich W, Kern L, Thiel S, Weber M, Paprotny M, Brugger S, Risch L, Bomze D, Flatz L. Severe Coronavirus Disease 2019 (COVID-19) is Associated With Elevated Serum Immunoglobulin (Ig) A and Antiphospholipid IgA Antibodies. *Clin Infect Dis* 2021; 73:e2869-e2874.

Bomze D, Asher N, Hasan A, Flatz L, Azoulay D, Markel G, Meirson T. Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors. *JAMA Netw Open* 2020; 3:e2017675.

Bomze D, Meirson T, Hasan A, Goldman A, Flatz L, Habet-Wilner Z. Ocular Adverse Events Induced by Immune Checkpoint Inhibitors: A Comprehensive Pharmacovigilance Analysis. *Ocul Immunol Inflamm* 2020:1-7.

Berner F, Bomze D, Flatz L. Immune-Related Adverse Events of Immune Checkpoint Inhibitors-From a Clinical to Pathophysiological View-In Reply. *JAMA Oncol* 2019

Hasan Ali O, Sadik C, Zillikens D, Schmidt E, Jochum W, Mani B, Cozzio A, Braun A, Emtenani S, Hammers C, Abdou M, Diem S, Fässler M, Berner F, Ring S, Bomze D, Flatz L. BP180-specific IgG is associated with skin adverse events, therapy response, and overall survival in non-small cell lung cancer patients treated with checkpoint inhibitors. *J Am Acad Dermatol* 2019; 82:854-861.

Bomze D, Hasan Ali O, Bate A, Flatz L. Association Between Immune-Related Adverse Events During Anti-PD-1 Therapy and Tumor Mutational Burden. *JAMA Oncol* 2019

Berner F, Hartmann F, Cheng H, Hönger G, Recher M, Goldman J, Cozzio A, Früh M, Neefjes J, Driessen C, Ludewig B, Hegazy A, Jochum W, Speiser D, Zippelius A, Läubli H, Bomze D, Diem S, Ali O, Fässler M, Ring S, Niederer R, Ackermann C, Baumgaertner P, Pikor N, Cruz C, van de Veen W, Akdis M, Nikolaev S, Flatz L. Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer. *JAMA Oncol* 2019; 5:1043-1047.

Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.

Fässler M, Jörger M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolík M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Hasan Ali O, Lenz T, Driessen C, Früh M, Jörger M, Cozzio A, Diem S, Fässler M, Bomze D, Berner F, Flatz L. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. *Eur J Cancer* 2018; 107:8-14.

Diem S, Hasan Ali O, Ackermann C, Bomze D, Koelzer V, Jochum W, Speiser D, Mertz K, Flatz L. Tumor infiltrating lymphocytes in lymph node metastases of stage III melanoma correspond to response and survival in nine patients treated with ipilimumab at the time of stage IV disease. *Cancer Immunol Immunother* 2017; 67:39-45.

Novkovic M, Turley S, Bocharov G, Stein J, Scandella E, Cremasco V, Bomze D, Abe J, Cupovic J, Onder L, Ludewig B. Topological Small-World Organization of the Fibroblastic Reticular Cell Network Determines Lymph Node Functionality. *PLoS Biol* 2016; 14:e1002515.

Onder L, Waisman A, Becher B, Ledermann B, Mair F, Maier R, Bomze D, Novkovic M, Caviezel-Firner S, Cheng H, Chai Q, Scandella E, Nindl V, Ludewig B. Alternative NF- κ B signaling regulates mTEC differentiation from podoplanin-expressing presursors in the cortico-medullary junction. *Eur J Immunol* 2015

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch